Tumor-Infiltrating Lymphocytes in the Treatment of Solid Tumors - Episode 5

Clinical Trial Data on TILs in Non-Small Cell Lung Cancer (NSCLC)

In the second installment of the series, Ben Creelan, MD, reviews clinical trial data and explains the rationale of using tumor-infiltrating lymphocytes (TILs) in non-small cell lung cancer (NSCLC) treatment.

EP. 1: Where Will Tumor-Infiltrating Lymphocyte (TIL) Therapy Fit Into the Oncologic Landscape?
EP. 2: Role of Tumor-Infiltrating Lymphocytes in Solid Tumors: Advancements in Therapeutic Strategy
EP. 3: TIL Therapy as a Personalized Treatment Strategy for NSCLC
EP. 4: Clinical Trials of TIL Therapy
Now Viewing
EP. 5: Clinical Trial Data on TILs in Non-Small Cell Lung Cancer (NSCLC)
EP. 6: Tumor-Infiltrating Lymphocytes: Rationale for Use in the Treatment of Solid Tumors and Potential Benefits and Drawbacks
EP. 7: Tumor Infiltrating Lymphocyte Data Signal Promise for New Options to Treat Advanced Melanoma